Efficacy and safety of low-dose propiverine in patients with lower urinary tract symptoms/benign prostatic hyperplasia with storage symptoms: A prospective, randomized, single-blinded and multicenter clinical trial

Korean Journal of Urology

Volumn 52, Issue 4, 2011, Pages 274-278

  Bae, Jae Hyun ^a   Kim, Sun Ouck ^b   Yoo, Eun Sang ^c   Moon, Kyung Hyun ^d   Kyung, Yoon Soo ^e   Kim, Hyung Jee ^e  

^a Korea University Ansan Hospital   (South Korea)

^b Chonnam National University Medical School   (South Korea)

^c Kyungpook National University   (South Korea)

^d Ulsan University College of Medicine   (South Korea)

^e Dankook University College of Medicine   (South Korea)

Author keywords

Cholinergic antagonists; Propiverine; Prostatic hyperplasia

Indexed keywords

ALFUZOSIN; PROPIVERINE;

ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; HUMAN; INTERNATIONAL PROSTATE SYMPTOM SCORE; LOW DRUG DOSE; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; MICTURITION DISORDER; MULTICENTER STUDY; POSTVOID RESIDUAL URINE VOLUME; PROSTATE HYPERTROPHY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TENESMUS; URINARY HESITANCY; URINE FLOW RATE;

EID: 79955695500     PISSN: 20056737     EISSN: 20056745     Source Type: Journal    
DOI: 10.4111/kju.2011.52.4.274     Document Type: Article

References (26)

1. Chapple CR, Smith D. The pathophysiological changes in the bladder obstructed by benign prostatic hyperplasia. Br J Urol 1994;73:117-23.
2. Park HK, Park H, Cho SY, Bae J, Jeong SJ, Hong SK, et al. The prevalence of benign prostatic hyperplasia in elderly men in Korea: a community-based study. Korean J Urol 2009;50:843-7.
3. Milsom I, Abrams P, Cardozo L, Roberts RG, Thüroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001;87:760-6.
4. Kim HW, Seo SI, Ko JS, Jung JH, Lee JY. Incidence of overactive bladder in benign prostatic hyperplasia and the efficacy of combination therapy of alpha blocker with tolterodine. Korean J Urol 2003;44:1006-10.
5. Abrams PH, Farrar DJ, Turner-Warwick RT, Whiteside CG, Feneley RC. The results of prostatectomy: a symptomatic and urodynamic analysis of 152 patients. J Urol 1979;121:640-2.
6. Kakizaki H, Machino R, Koyanagi T. Clinical experience in lower urinary tract symptoms. BJU Int 2001;88(Suppl 2):23-6.
7. Seaman EK, Jacobs BZ, Blaivas JG, Kaplan SA. Persistence or recurrence of symptoms after transurethral resection of the prostate: a urodynamic assessment. J Urol 1994;152:935-7.
8. Engström G, Henningsohn L, Walker-Engström ML, Leppert J. Impact on quality of life of different lower urinary tract symptoms in men measured by means of the SF 36 questionnaire. Scand J Urol Nephrol 2006;40:485-94.
9. Sountoulides P, van Dijk MM, Wijkstra H, de la Rosette JJ, Michel MC. Role of voiding and storage symptoms for the quality of life before and after treatment in men with voiding dysfunction. World J Urol 2010;28:3-8.
10. Chapple CR, Rechberger T, Al-Shukri S, Meffan P, Everaert K, Huang M, et al. Randomized, double-blind placebo-and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 2004;93:303-10.
11. Otsuka A, Shinbo H, Hasebe K, Matsumoto R, Ozono S. Effects of a novel beta(3)-adrenoceptor agonist, AJ-9677, on relaxation of the detrusor muscle: an in vitro study. Int J Urol 2008;15:1072-6.
12. Zagorodnyuk VP, Brookes SJ, Spencer NJ, Gregory S. Mechanotransduction and chemosensitivity of two major classes of bladder afferents with endings in the vicinity to the urothelium. J Physiol 2009;587:3523-38.
13. Jang J, Park EY, Seo SI, Hwang TK, Kim JC. Effects of intravesical instillation of cyclooxygenase-2 inhibitor on the expression of inducible nitric oxide synthase and nerve growth factor in cyclophosphamide-induced overactive bladder. BJU Int 2006;98:435-9.
14. Abrams P, Kaplan S, De Koning Gans HJ, Millard R. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol 2006;175:999-1004.
15. Kaplan SA, Roehrborn CG, Rovner ES, Carlsson M, Bavendam T, Guan Z. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA 2006;296:2319-28.
16. Lee KS, Choo MS, Kim DY, Kim JC, Kim HJ, Min KS, et al. Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study. J Urol 2005;174:1334-8.
17. Staskin DR, Rosenberg MT, Dahl NV, Polishuk PV, Zinner NR. Effects of oxybutynin transdermal system on health-related quality of life and safety in men with overactive bladder and prostate conditions. Int J Clin Pract 2008;62:27-38.
18. Irani J. Anticholinergic drugs in patients with bladder outlet obstruction and lower urinary tract symptoms: Where do we stand in 2006? Eur Urol 2006;50:653-4.
19. Novara G, Galfano A, Ficarra V, Artibani W. Anticholinergic drugs in patients with bladder outlet obstruction and lower urinary tract symptoms: a systematic review. Eur Urol 2006;50:675-83.
20. Rackley R, Weiss JP, Rovner ES, Wang JT, Guan Z. Nighttime dosing with tolterodine reduces overactive bladder-related nocturnal micturitions in patients with overactive bladder and nocturia. Urology 2006;67:731-6.
21. Feinberg M. The problems of anticholinergic adverse effects in older patients. Drugs Aging 1993;3:335-48.
22. Hong WS, Chung H, Lee JM, Kim TW, Kim HS, Kim HJ, et al. Polypharmacy and central nervous system adverse effects of anticholinergic agents in the men with benign prostate hyperplasia. J Korean Continence Soc 2007;11:24-9.
23. Abrams P, Freeman R, Anderström C, Mattiasson A. Tolterodine, a new antimuscarinic agent: as effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol 1998; 81:801-10.
24. Kelleher CJ, Cardozo LD, Khullar V, Salvatore S. A medium-term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance. Br J Obstet Gynaecol 1997;104:988-93.
25. Milsom I, Abrams P, Cardozo L, Roberts RG, Thüroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001;87:760-6.
26. Versi E, Appell R, Mobley D, Patton W, Saltzstein D. Dry mouth with conventional and controlled-release oxybutynin in urinary incontinence. The Ditropan XL Study Group. Obstet Gynecol 2000;95:718-21.